Gilead Avoids $2.5bn Jury Verdict As Judge Rules Merck's Hep C Patent Is Invalid
Merck to appeal decision after district court says Gilead's discovery of sofosbuvir was 'neither routine nor simple.'
You may also be interested in...
Reversal In CAR-T Patent Battle Shows Federal Circuit’s Preference For Narrow Claims
Appeals court finds that Juno/BMS patent is invalid, overturning $1.2bn jury verdict against Kite/Gilead. Ruling illustrates court does not like functionally-defined patent claims, attorneys say. Decision could impact future CAR-T patents and disputes.
After Hep C Patent Battle, Gilead Faces ViiV Suit Over Its New HIV Drug
Complaint says similarities between Gilead's Biktarvy and ViiV's dolutegravir suggest Gilead copied ViiV's drug.
Brand vs. Brand Patent Battles Heat Up, Focus On Big Drug Classes
Patent brawl between Merck and Gilead involving Sovaldi and Harvoni was one of the marquee litigation events of 2016; a compilation of disputes between brand-name companies over the past six years shows how consequential they can be.